3(5)-tributylstannylpyrazole | 141998-84-7

• 分子结构分类: 有机化合物 - 有机金属化合物 - 金属芳基
• 英文名称: 3(5)-tributylstannylpyrazole
• 英文别名: 3-(tributylstannyl)-1H-pyrazole；3-(tributylstannyl)pyrazole；tributyl(1H-pyrazol-5-yl)stannane
• CAS: 141998-84-7
• 化学式: C₁₅H₃₀N₂Sn
• 分子量: 357.127
• InChiKey: DJPWGOLOEFKKFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.47
• 重原子数：
  18
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3(5)-tributylstannylpyrazole 在 碘 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以63%的产率得到3-碘吡唑
  参考文献：
  名称：

  Sakamoto, Takao; Shiga, Futoshi; Uchiyama, Daishi, Heterocycles, 1992, vol. 33, # 2, p. 813 - 818

  摘要：

  DOI：

文献信息

• DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS
  申请人：Wang Tao

  公开号：US20070249579A1

  公开（公告）日：2007-10-25

  This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.

  本公开提供具有药物和生物影响特性的化合物，它们的药物组合物和使用方法。具体而言，该公开涉及具有独特抗病毒活性的二酮哌嗪和哌啶衍生物。更具体地说，本公开涉及用于治疗艾滋病毒和艾滋病的化合物。
• Indole, azaindole and related heterocyclic pyrrolidine derivatives
  申请人：——

  公开号：US20030236277A1

  公开（公告）日：2003-12-25

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with amido piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

  这项发明提供了具有药物和生物影响特性的化合物，它们的药物组合物和使用方法。具体来说，该发明涉及酰胺哌嗪衍生物。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药物、抗感染剂、免疫调节剂或HIV进入抑制剂结合使用。更具体地，本发明涉及HIV和艾滋病的治疗。
• Diazaindole-dicarbonyl-piperazinyl antiviral agents
  申请人：Bender A. John

  公开号：US20050124623A1

  公开（公告）日：2005-06-09

  The invention comprises substituted diazaindole-dicarbonyl-piperazinyl derivatives of general Formula I wherein: Q is selected from the group consisting of — may represent a bond; T is —C(O)— or —CH(CN)—; and —Y— is selected from the group consisting of compositions thereof and their use for treating HIV infection.

  这项发明包括通式I的替代二氮杂吲哚-二羰基-哌嗪基衍生物，其中：Q选自由一组，可以表示成键；T为—C(O)—或—CH(CN)—；以及—Y—选自由一组，包括其组成物及其用于治疗HIV感染的用途。
• Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment. 12. Structure–Activity Relationships Associated with 4-Fluoro-6-azaindole Derivatives Leading to the Identification of 1-(4-Benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-3-yl)ethane-1,2-dione (BMS-585248)
  作者：Alicia Regueiro-Ren、Qiufen M. Xue、Jacob J. Swidorski、Yi-Fei Gong、Marina Mathew、Dawn D. Parker、Zheng Yang、Betsy Eggers、Celia D’Arienzo、Yongnian Sun、Jacek Malinowski、Qi Gao、Dedong Wu、David R. Langley、Richard J. Colonno、Caly Chien、Dennis M. Grasela、Ming Zheng、Pin-Fang Lin、Nicholas A. Meanwell、John F. Kadow

  DOI：10.1021/jm3016377

  日期：2013.2.28

  A series of highly potent HIV-1 attachment inhibitors with 4-fluoro-6-azaindole core heterocycles that target the viral envelope protein gp120 has been prepared. Substitution in the 7-position of the azaindole core with amides (12a,b), C-linked heterocycles (12c-I), and N-linked heterocycles (12m-u) provided compounds with subnanomolar potency in a pseudotype infectivity assay and good pharmacokinetic profiles in vivo. A predictive model was developed from the initial SAR in which the potency of the analogues correlated with the ability of the substituent in the 7-position of the azaindole to adopt a coplanar conformation by either forming internal hydrogen bonds or avoiding repulsive substitution patterns. 1-(4-Benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248, 12m) exhibited much improved in vitro potency and pharmacokinetic properties than the previous clinical candidate BMS-488043 (1). The predicted low clearance in humans, modest protein binding, and good potency in the presence of 40% human serum for 12m led to its selection for human clinical studies.
• Sakamoto, Takao; Shiga, Futoshi; Uchiyama, Daishi, Heterocycles, 1992, vol. 33, # 2, p. 813 - 818
  作者：Sakamoto, Takao、Shiga, Futoshi、Uchiyama, Daishi、Kondo, Yoshinori、Yamanaka, Hiroshi

  DOI：——

  日期：——